Loading paragraph...
Today's Biggest Stock Losers
| Symbol | Name | Last Price | Change | % Change | Volume | Market Cap | 52-Week Range |
|---|---|---|---|---|---|---|---|
| EMAT | Evolution Metals & Technologies | $9.51 | -$6.94 | -42.19% | 1.5K | $27M | $7.05$24.37 |
| RGC | Regencell Bioscience | $32.54 | -$11.57 | -26.23% | 4.2K | $16B | $0.09$83.60 |
| ATRA | Atara Biotherapeutics | $4.37 | -$1.51 | -25.68% | 5.9K | $32M | $4.25$19.15 |
| ELAB | Pmgc | $4.02 | -$1.25 | -23.72% | 1.9K | $2.0M | $3.54$398.86 |
| PASG | Passage Bio | $14.27 | -$3.64 | -20.32% | 101.1K | $45M | $5.12$20.00 |
| CVRX | CVRx | $6.11 | -$1.20 | -16.42% | 945 | $160M | $4.30$18.55 |
| FIGG | Themes ETF Trust - Leverage Shares 2x Long Fig Daily ETF | $3.64 | -$0.68 | -15.66% | 351 | - | $3.53$16.34 |
| TVTX | Travere Therapeutics | $29.11 | -$4.99 | -14.63% | 1.7K | $2.6B | $12.91$42.13 |
| ZEPP | Zepp Health | $22.81 | -$3.87 | -14.51% | 152.6K | $161M | $2.13$61.85 |
| CRMG | Themes ETF Trust - Leverage Shares 2x Long Crm Daily ETF | $11.21 | -$1.85 | -14.16% | 669 | - | $9.86$19.41 |
Related Articles
Featured Article
A Nearly 1,100% Gain: Here's the 1 Key Reason Why This Forgotten Tech Stock Crushed the S&P 500
Scott Levine|Dec 5, 2025
After years of struggling with one key metric, this tech company has found its way back onto investors' buy lists.
This Stock Soared 9,800% in 2025. Here's 1 Key Reason Why Investors Are Piling In (Spoiler: It's Regencell Bioscience Holdings (RGC) Stock)
Selena Maranjian|Nov 24, 2025
Is the stock likely to keep surging? The answer seems pretty clear.
This Fitness Tech Stock Has Crushed Apple's 2025 Gains -- 1 Reason Why
Lyle Daly|Oct 19, 2025
The Amazfit brand has helped Zepp Health bounce back in a big way after years of negative returns.
Advertisement
These 5 Companies Were Huge Winners This Earnings Season. Can the Good Times Keep Rolling?
Jon Quast|Nov 10, 2023
One of these five stocks is trading at a low price and has a profit catalyst that's greater than anything on the horizon for the other four.
Could an FDA Approval Send This Stock Flying?
David Jagielski, CPA|Mar 1, 2023
Is now the time to load up on this struggling stock?
This Expert Says Companies Need to Constantly Align Their Strategy and Culture
Motley Fool Staff|Jun 24, 2022
It can lead to successful outcomes in a variety of ways.
If This 1 Thing Happens in 2022, I'll Buy This Under-the-Radar IPO Stock in a Heartbeat
Jon Quast|Jan 20, 2022
The company zigged where its competitors zagged, jump-starting an important long-term growth engine.
IPO Stock Udemy's Profit Margins Are Better Than They Look
Jon Quast|Nov 10, 2021
The company has the financial profile investors have come to love with marketplace businesses.
Does IPO Stock Udemy Have a Competitive Advantage?
Jon Quast and Travis Hoium|Nov 9, 2021
The key to a two-sided marketplace is to open both funnels as wide as possible and Udemy is doing that.
2 Steps to Biotech Success: Good Data, Then Raise Capital
Brian Orelli, PhD|Dec 23, 2020
Companies that don't do the second step won't last long in this industry.
![Biotech_Stocks_Step_1_Good_Data,_Step_2_Raise_Capital[1]](https://g.foolcdn.com/image/?url=https%3A%2F%2Fg.foolcdn.com%2Feditorial%2Fimages%2F605702%2Fbiotech_stocks_step_1_good_data_step_2_raise_capital1.jpg&w=384&op=resize)